[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368291-105":59,"doc-detail-368291-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","palb2-germline-pathogenic-variants-frequency-clinical-features-and-functional-analysis-of-c3350d5ga-variant-in-3987-korean-cancer-patients-research","PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350D5G>A variant in 3987 Korean cancer patients - Research","","PALB2 germline variants increase risks of multiple cancers, yet Korean evidence has remained insufficient. This study analyzed clinicopathological data and germline next-generation sequencing from 3987 Korean cancer patients at the National Cancer Center. Functional assays evaluated the PALB2 splicing variant c.3350+5G>A. PALB2 PVs/LPVs were found in 0.6% overall, predominantly among women with breast or ovarian cancer. The variant was reclassified as PV using ACMG guidelines. Younger age at first diagnosis and multiple primary organ cancers marked carriers, supporting targeted screening and family genetic testing.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/palb2-germline-pathogenic-variants-frequency-clinical-features-and-functional-analysis-of-c3350d5ga-variant-in-3987-korean-cancer-patients-research/368291/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/palb2-germline-pathogenic-variants-frequency-clinical-features-and-functional-analysis-of-c3350d5ga-variant-in-3987-korean-cancer-patients-research/368291.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary goal of this study?","Question",{"text":113,"@type":114},"To determine the prevalence and clinical characteristics of PALB2 germline variants in Korean cancer patients and compare findings with existing data, including functional evaluation of a specific splicing variant.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How common were PALB2 PVs/LPVs among the 3987 patients?",{"text":118,"@type":114},"PALB2 PVs/LPVs were detected at an overall frequency of 0.6% (22/3987) across all included patients.",{"name":120,"@type":111,"acceptedAnswer":121},"Which clinical factors distinguished carriers of PALB2 PVs/LPVs?",{"text":122,"@type":114},"Carriers had a younger age at first cancer diagnosis and were more likely to have multiple primary organ cancer diagnoses than non-carriers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368291,1790519207,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ORIGINAL RESEARCH  \nPALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350D5G>A variant in 3987 Korean cancer patients  \nM.-C. Kang1, S. Lee2, H. Kim1, H.-S. Kang2, S.-Y. Jung2, J.-A. Hwang3, J. Kwon4, K. S. Lee2, M. C. Lim5, S.-Y. Park5, S. H. Sim2, W. Choi6, J. E. Park7, E.-H. Cho8 & S.-Y. Kong1, 9 , 10􀀁  \n1Targeted Therapy Branch, National Cancer Center, Goyang; 2Center for Breast Cancer, National Cancer Center, Goyang; 3Genomics Core Facility, Research Core Center, National Cancer Center, Goyang; 4Bioinformatics Branch, National Cancer Center, Goyang; 5Center for Gynecologic Cancer, National Cancer Center, Goyang; 6Center for Rare Cancers, National Cancer Center, Goyang; 7Department of Laboratory Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri; 8Genome Research Center, GC Genome, Yongin; 9Cancer Biomedical Science, National Cancer Center, Goyang; 10Department of Laboratory Medicine, National Cancer Center, Goyang, Republic of Korea  \nAvailable online xxx  \nBackground: Germline PALB2 variants increase the risks of various cancers. However, these have not been comprehensively investigated in Korean patients with cancer. Our study aimed to evaluate the prevalence and clinical characteristics of PALB2 germline variants in Korean patients with cancer and compare these ﬁndings with existing data.  \nPatients and methods: We analyzed the clinicopathological and germline next-generation sequencing data of 3987 patients with cancer from the National Cancer Center in Korea. Additionally, we carried out functional analysis of the PALB2 splicing variant, c.3350þ5G>A.  \nResults: A total of 104 patients presented PALB2 germline variants with eight pathogenic variants (PVs), 14 likely pathogenic variants (LPVs), and 82 variants of uncertain signiﬁcance (VUS) . PALB2 PV/LPVs were detected at an overall frequency of 0 .6%(22/3987) across all patients. Among patients with PV/LPVs, 95 .5% were women, and 19 and 3 carriers were diagnosed with breast and ovarian cancer, respectively. Further, we reclassiﬁed c.3350þ5G>Aas a PV rather than VUS, according to the American College of Medical Genetics and Genomics guidelines. Patients with PALB2 PV/LPVs had a younger age at ﬁrst cancer diagnosis (44 .6 􀀃 10. 1 years versus 50 .2 􀀃 12.0 years, P ¼ 0.019) and were more likely to have multiple primary organ cancer diagnoses (22 .7% versus 8 .3%, P ¼ 0.032) compared with those without these variants.  \nConclusion: Age at ﬁrst cancer diagnosis and the presence of multiple primary organ cancers are key risk factors for suspected germline PALB2 PV. Hence, strategies are required to improve adherence to the National Comprehensive Cancer Network guidelines for cancer screening and family genetic testing among Korean patients with cancer. Key words: genetic counseling, breast cancer, ovarian cancer, PALB2  \nINTRODUCTION  \nGenetic susceptibilities signiﬁcantly inﬂuence the emergence of various types of cancer.1 Since their identiﬁcation in the 1990s, BRCA1 and BRCA2 have become well established as signiﬁcant predisposition factors for breast, ovarian, prostate, and pancreatic cancer.2-4 Moreover, the advent of multigene panel testing has led to the discovery of additional cancer susceptibility genes, including PALB2  \n*Correspondence to: Prof. Sun-Young Kong, Department of Laboratory Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Tel: þ82-31-920-1735; Fax: þ82-31-920-1337  \nE-mail: [ksy@ncc.re.kr](ksy@ncc.re.kr) (S.-Y. Kong).  \n2059-7029/© 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n(partner and localizer of BRCA2), which play a signiﬁcant role in hereditary cancer risk.5  \nPALB2 (NM_024675.4) acts as a tumor suppressor gene","cbCaiskpELqwq2ux","https://ap.wps.com/l/cbCaiskpELqwq2ux","pdf",1451226,"English","# Background\n# Patients and methods\n## Functional analysis\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What was the primary goal of this study?\",\"answer\":\"To determine the prevalence and clinical characteristics of PALB2 germline variants in Korean cancer patients and compare findings with existing data, including functional evaluation of a specific splicing variant.\"},{\"question\":\"How common were PALB2 PVs/LPVs among the 3987 patients?\",\"answer\":\"PALB2 PVs/LPVs were detected at an overall frequency of 0.6% (22/3987) across all included patients.\"},{\"question\":\"Which clinical factors distinguished carriers of PALB2 PVs/LPVs?\",\"answer\":\"Carriers had a younger age at first cancer diagnosis and were more likely to have multiple primary organ cancer diagnoses than non-carriers.\"}]","PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350D5G>A variant in 3987 Korean cancer patients - Research | PDF",1790176063,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1feeea8fc13ee76e98cbdad8845f235.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/342446f8b7a882eb798e9e674475f995.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6699b5eab53ed01be8d9330cacc0da1.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2f68d2f27b8a2afda43b2a5bb657dd5.webp",980,1265]